Insulin-like growth factor 1 associated research in Alzheimer's disease: an exploratory trends analysis.
Research on IGF-1 and Alzheimer's disease is growing, with a notable increase in publications and a focus on underlying mechanisms.
Where it sits
this study against the rest of the mk-677 (ibutamoren) corpusSummary and findings
This study analyzed the research trends related to insulin-like growth factor-1 (IGF-1) in Alzheimer's disease (AD) by reviewing 632 publications. The analysis highlighted the geographical distribution of research and identified key authors and institutions in the field. No specific dose or treatment outcomes were reported.
Abstract
<h4>Background</h4>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive impairment and behavioral deterioration. In recent years, the role of the insulin-like growth factor-1 (IGF-1) signaling pathway in the pathological process of AD has received increasing attention. This study provides a visual analysis of the current research status, development trends, collaboration networks, and research hotspots related to IGF-1 and AD.<h4>Methods</h4>Publications were retrieved from the Web of Science and Scopus databases. CiteSpace, VOSviewer, and Bibliometrix software were used for visual analysis.<h4>Results</h4>A total of 632 publications were included in the study. The annual publications related to IGF-1 and AD exhibited an overall upward trend. Research was concentrated in North America, Asia, and Europe. The United States holds a dominant position in terms of output, influence, and international influence. The Consejo Superior de Investigaciones Científicas was the most active institution. <i>Journal of Alzheimer's Disease</i> was the journal with the highest number of publications. Dr. Ignacio Torres-Aleman was the most prolific author. High-frequency keywords included IGF-1, AD, brain, insulin, controlled study, metabolism, oxidative stress, animals, signal transduction, amyloid beta protein, dementia, aging, and neuroprotection. Transgenic mouse, risk, depression, and cognitive impairment were the most powerful keywords that have emerged in recent years.<h4>Conclusion</h4>Research on IGF-1 and AD has continued to grow. Studies in this field have formed a tightly interconnected network, centered on the AD pathological core-IGF-1-related molecular mechanisms-downstream signaling pathways. The research focus is shifting from superficial correlations to investigations into underlying mechanisms and potential therapeutic targets. Depression and cognitive impairment are likely to become promising frontiers for future research.
Background
The paper addresses the relationship between insulin-like growth factor 1 (IGF-1) and Alzheimer's disease, a condition characterized by cognitive decline and neurodegeneration. Prior research has suggested a potential role of IGF-1 in neuroprotection and cognitive function, but the specific trends and associations in Alzheimer's disease require further exploration. This study aims to contribute to the understanding of IGF-1's role in this context.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.